# Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

> clinical trial · VERIFIED · 2026-07-31

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Metastatic Head and Neck Squamous Cell Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: Metastatic Head and Neck Squamous Cell Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT06589804

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.